1. [Progression and application of circulating tumor DNA in lymphoma].
- Author
-
Huang DZ, Zhang X, and Rao J
- Subjects
- Humans, Mutation, Biomarkers, Tumor blood, Biomarkers, Tumor genetics, Circulating Tumor DNA blood, Circulating Tumor DNA genetics, Lymphoma diagnosis, Lymphoma blood, Lymphoma genetics
- Abstract
Lymphomas are a highly heterogeneous group of tumors that are classified into several subtypes. The gold standard method for the molecular profiling of lymphoma is based on invasive lymph node or tissue biopsy. However, this method cannot accurately capture spatial tumor heterogeneity in each patient as well as systemic tumor invasion and tumor burden. Circulating tumor DNA (ctDNA) is an emerging and highly versatile biomarker that overcomes the basic limitations of imaging scanning and tissue biopsy; has the characteristics of being simple, rapid, and non-invasive; and has good specificity and high sensitivity. ctDNA testing has been applied to a variety of subtypes of lymphoma and has been used for somatic mutation genotyping, efficacy monitoring during treatment, detection of minimal residual disease, and the prediction of survival, which may help clinicians make better clinical decisions in the diagnosis and treatment of lymphoma patients. Furthermore, this study also aims to review the different methods of ctDNA analysis and describe the specific applications of ctDNA in different lymphoma subtypes.
- Published
- 2024
- Full Text
- View/download PDF